Management of rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 9, Issue 3, 1997, Pages 229-235

  Stucki, Gerold ^a   Langenegger, Thomas ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

ALGORITHM; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE COURSE; EARLY DIAGNOSIS; FEEDBACK SYSTEM; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL EDUCATION; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SIDE EFFECT;

ARTHRITIS, RHEUMATOID; FORECASTING; HUMANS; QUALITY ASSURANCE, HEALTH CARE; REFERRAL AND CONSULTATION; RHEUMATOLOGY;

EID: 0030977444     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199705000-00009     Document Type: Review

References (42)

1. Stucki G, Sangha O: Clinical quality management: putting the pieces together. Arthritis Care Res 1996, 9:405-412.
2. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J: Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996, 39:616-622. Analytic cohort study of 2888 RA patients followed prospectively for an average of 9 years at 8 ARAMIS databank centers. Increased DMARD use was strongly associated with better long-term disability index values.
3. van der Heide A, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, van Booma-Frankfort C, van der Veen MJ, Haanen HCM, Hofman DM: The effectiveness of early treatment with "second line" antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996, 124:699-707. Open, randomized clinical trial of delayed versus immediate introduction of DMARD treatment. In an intention-to-treat analysis, patients on immediate treatment had statistically significant and clinically relevant better scores with respect to physical functional disability, pain, joint score, and erythrocyte sedimentation rate and occurrence and progression of radiologie changes at 12 months. While only 8% of patients on immediate DMARD treatment stopped treatment usually because of adverse reactions, 29% of patients in the delayed DMARD group stopped the non-DMARD regimen due to ineffectiveness.
4. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, Trang L: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled Study. J Rheumatol 1995, 22(12):2208-2213.
5. Kwoh KC, Simms RW, Anderson LG, Erlandson DM, Greene JM, Moncur C, O'Dell JR, Partridge AJ, Roberts WN, Robbins ML, et al. for the American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996, 39:713-722. Guidelines developed in collaboration by rheumatologists and primary care physicians suggesting that patients with polyarthritis be referred to rheumatologist evaluation and, if appropriate, initiation of DMARD treatment. Separate guidelines address the monitoring of medications used in the treatment of RA.
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
7. Panush RS, Carias K, Kramer N, Rosenstein ED: Acute arthritis in the hospital: comparison of rheumatologic with nonrheumatologic care. Clin Rheumatol 1995, 1:74-80.
8. Chan KW, Felson DT, Yood RA, Walker AM: The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994, 37:814-820.
9. Hicks NR, Baker IA: General practitioners' opinions of health services available to their patients. BMJ 1991, 302:991-993.
10. Smith EC, Berry H, Scott DL: The clinical need for an acute rheumatology referral service. Br J Rheumatol 1996, 35:389-391.
11. Armstrong D, Fry J, Armstrong P: Doctors' perceptions of pressure from patients for referral. BMJ 1991, 302:1186-1188.
12. Bjelle A, Magi M: Rheumatic disorders in primary care: a study of two primary care centres and a review of previous Swedish reports on primary care. Scand J Rheumatol 1981, 10:331-341.
13. Harrison BJ, Symmons DPM, Brennan P, Barrett EM, Silman AJ: Natural remission in inflammatory polyarthritis: Issues of definition and prediction. Br J Rheumatol 1996, 35:1096-1100. Inception cohort of patients with inflammatory polyarthritis in the community examining the usefulness of information currently available in clinical practice. These authors confirmed the known association of men with fewer than six tender joints at baseline in remission. It was not possible however to construct a prediction rule of enough certainty to be useful in clinical decision making. The rate of remission in patients with inflammatory polyarthritis after 2 years was only 25% and only 9% of all patients were in "sustained remission" after both 1 and 2 years.
14. Prevoo MLL, van Gestel AM, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM: Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the Disease Activity Score. Br J Rheumatol 1996, 35:1101-5. Although 25% of patients fulfilled at least once the criteria for remission during the study period, only 15% fulfilled the criteria at two consecutive visits. These exemplary case studies show that visits in which patients are in remission are not always consecutive. Remission thus may be best understood as a temporary state in the continuum of systemic inflammation or disease activity.
15. Stucki G, Liang MH, Stucki S, Brühlmann P, Michel BA: A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiological research: psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995, 6:795-798.
16. Fries JF, Spitz PW, Kraines RG, Holman HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145.
17. van der Heijde DMFM, van't Hof MA, van Riel PLCM, van Leeuwen MA, van Rijswijk MH, van de Putte LBA: Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992, 51:177-181.
18. van Gestel AM, Prevoo MLL, Van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996, 39:34-40. These authors clearly showed that what physicians describe as disease activity and criteria that they employ in their decision making with regard to DMARD-treatment can be measured with a few weighted variables. With an algorithm termed Disease Activity Score (DAS), which integrates the number of swollen, tender joints and sedimentation rate, disease activity can be quantified on a continuum from zero to ten. Depending on initial disease activity, a change of 0.6 to 1.2 represents a clinically relevant change.
19. Pinals RS, Masi AT, Larsen A: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308-1315.
20. Deyo RA, Patrick DL: Barriers to the use of health status measures in clinical investigation, patient care, and policy research. Med Care 1989, 27:254-268.
21. Wolfe F: The epidemiology of drug treatement failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995, 9:619-632.
22. Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M: Survival of drug discontinuation analysis in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995, 54:708-712.
23. De la Mata J, Blanco FJ, Gomez-Reino JJ: Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis 1995, 54:881-885.
24. Borigini MJ, Paulus HE: Combination therapy. Baillieres Clin Rheumatol 1995, 9:689-710.
25. O'Dell J, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-1291. A report of a controlled, 2-year, double-blind, randomized clinical trial comparing methotrexate alone with sulfasalazine and hydroxychloroquine and with a triple combination therapy with all drugs. Combining the three drugs was more effective and not more toxic than methotrexate alone, or the combination of hydroxychloroquine and sulfasalazine.
26. Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R: Comparison of azathioprine, methotrexate, and the combination of the two in the treatement of rheumatoid arthritis. Arthritis Rheum 1995, 38:1799-1806.
27. Salaffi F, Carotti M, Cervini C: Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis. Scand J Rheumatol 1996, 25:16-23.
28. Boers M, Verhoeven AC, Markusse HM, Westhovens R, van de Laar MAFJ, van Denderen JC, van Zeben J, Dijkmans BAC, Peeters A, Jacobs P, et al.: Combination of step down steroids, methotrexate, and sulfasalazine in early rheumatoid arthritis (COBRA trial). Arthritis Rheum 1996, 39(suppl):S104.
29. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, Koopman WJ: Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-1412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995, 38:1581-1588.
30. Van Riel PLCM: Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis. Br J Rheumatol 1992, 31:793-794.
31. Ferraz MB, Pinheiro GRC, Helfenstein M, Albuquerque E, Rezende C, Roimicher L, Brandao L, Silva SC, Pinheiro GC, Atra E: Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. Scand J Rheumatol 1994, 23:231-236.
32. Faarwang KL, Egsmose C, Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM: Hydroxychloroquine and sulfasalazine alone and in combination in rheumatoid arthritis: a randomized double blind trial. Ann Rheum Dis 1993, 52:711-715.
33. Williams JH, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, Weismann MH, Willkens RF, Singer JZ, Alarcon GS, et al.: Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum 1992, 35: 259-269.
34. Scott DL, Dawes PT, Tunn E, Fowler PD, Shadforth MF, Fisher J, Clarke S, Collins M, Jones P, Poper AJ, Bacon PA: Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. Br J Rheumatol 1989, 28:128-133.
35. Taggart AJ, Hill J, Astbury C, Dixon JS, Bird HA, Wright V: Sulfasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. Br J Rheumatol, 1987: 26:32-36.
36. Bunch TW, O'Duffy JD, Tompkins RB, O'Fallon WM: Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatement of rheumatoid arthritis. Arthritis Rheum 1984, 27:267-276.
37. Tugwell P, Pincus Th, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker Ph, Wells G: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995, 333:137-141.
38. Haagsma CJ, van Riel PLCM, de Rooij DJRAM, Vree TB, Russel FJM, van't Hof MA, van de Putte LBA: Combination of methotrexate and sulfasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulfasalazine therapy. Br J Rheumatol 1994, 33:1049-1055.
39. Haagsma CJ, van Riel PLCM, van de Putte LBA: Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions. Br J Rheumatol 1995, 34(suppl2):104-108.
40. Porler DR, Capell HA, Hunter J: Combination therapy in rheumatoid arthritis: no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol 1993, 20:645-649.
41. Farr M, Kitas G, Bacon PA: Sulfasalazine in rheumatoid arthritis, combination therapy with D-penicillamine or sodium aurothiomalate. Clin Rheumatol 1988, 7:242-248.
42. Schwarzer AC, Arnold MH, Kelly D, Jones M, Beller E, McNaught PJ, Schrieber L, Brooks PM: The cycling of combination drug therapy in rheumatoid arthritis. Br J Rheumatol 1990, 29:445-450.